3rd March 2022|Commercial Media, News Latest LPLDL® human intervention study from ProBiotix Health highlights ‘promising findings’ on cholesterol reduction
9th February 2022|Commercial Media, News OptiBiotix targets sports nutrition market with launch of LeanBiome™
8th February 2022|Commercial Media, News OptiBiotix signs exclusive sales and distribution agreement with leading Saudi pharma chain, Nahdi Medical Co
3rd February 2022|Commercial Media, News British Retail Consortium Accreditation backs OptiBiotix health and wellness solutions
19th January 2022|News, Scientific Media LPLDL® from ProBiotix Health showcases statistically significant reductions in multiple coronary heart disease biomarkers in hypercholesterolemic adults
18th January 2022|Investor Media, News Paul Cannings appointed Head of Operations & Quality at OptiBiotix
